Drug intelligence / Profile preview

SENS-01

Development stage: Preclinical
Lead developer: Sensorium Therapeutics
Modality: Small Molecules

Overview

SENS-01 is an experimental small molecule drug under development by Sensorium Therapeutics for the treatment of anxiety disorders, including social anxiety disorder, and depressive disorders. It is described as a novel, highly selective, and fast-acting anxiolytic that does not cause sedation. The compound is a synthetic analogue of a naturally occurring anxiolytic validated in humans. While its exact mechanism of action has not been disclosed publicly, it is differentiated from current standard-of-care treatments and inspired by natural compounds with proven human efficacy and safety data. As of October 2024, SENS-01 remains in preclinical development with plans to enter clinical trials in early 2025[1][3][4][5].

Other names: Formerly known as SENS-01

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on SENS-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENS-01.

Explore the full profile